Skip to main content
main-content

Prostate cancer

Prostate cancer

10-05-2022 | Oncology | News | Article

Prostate cancer death linked to increases in BMI, waist size

A meta-analysis has identified a significantly elevated risk for prostate cancer-specific mortality with increases in BMI, waist circumference, and waist-to-hip ratio.

29-04-2022 | Oncology | News | Article

Pharmacovigilance data show prostate cancer hormone therapy link to neurocognitive decline

Both traditional hormone therapy and novel androgen receptor signaling inhibitors may be associated with neurocognitive impairment in men with prostate cancer, suggests WHO pharmacovigilance data.

13-04-2022 | Oncology | News | Article

Enhanced mortality risk reduction with adjuvant RT in men with LN-positive prostate cancer

All-cause mortality is significantly reduced in men with prostate cancer receiving adjuvant versus early salvage radiotherapy, particularly if they have four or more positive pelvic lymph nodes, research suggests.

11-04-2022 | Oncology | News | Article

Bone screening uncommon in men given ADT for prostate cancer

Fewer than one in 10 older men initiating androgen deprivation therapy for localized or regional prostate cancer receive dual-energy x-ray absorptiometry screening to assess bone mineral density, US study findings indicate.

06-04-2022 | Oncology | News | Article

​​​​​​​PSMA-targeted radioligand therapy approved for US mCRPC patients

More information about this FDA announcement here

18-03-2022 | Oncology | News | Article

Screening MRI unnecessary to prevent mCRPC spinal cord compression

Magnetic resonance imaging screening plus pre-emptive treatment does not significantly reduce clinical spinal cord compression rates in patients with castration-resistant prostate cancer and spinal metastasis, PROMPTS trial data show.

04-03-2022 | Oncology | News | Article

CADMUS suggests role for multiparametric ultrasound in diagnosing prostate cancer

The CADMUS investigators report a “slightly lower” rate of detection of clinically significant prostate cancers with multiparametric ultrasound than multiparametric MRI, but a higher rate of referrals for biopsy.

01-03-2022 | Oncology | News | Article

EMA supports use of relugolix for prostate cancer

Read more on this recommendation here

28-02-2022 | Oncology | News | Article

DCVAC/PCa use alongside chemotherapy shows no additional mCRPC survival benefit

The active autologous dendritic cell-based immunotherapy DCVAC/PCa is well tolerated when combined with docetaxel plus prednisone but does not improve survival in men with metastatic castration-resistant prostate cancer, phase 3 study data show.

19-02-2022 | Oncology | News | Article

PRESIDE shows clinical benefit of continuing enzalutamide post progression

Continuing enzalutamide treatment in combination with docetaxel reduces the risk for progression versus placebo plus docetaxel in men with metastatic castration-resistant prostate cancer that progressed during enzalutamide monotherapy, PRESIDE study data show.

18-02-2022 | Oncology | News | Article

Early mCRPC promise shown for novel CYP11A1 inhibitor

ODM-208, a novel nonsteroidal inhibitor of CYP11A1, has demonstrated promising antitumor activity in previously treated patients with metastatic castration-resistant prostate cancer enrolled in the first-in-human CYPIDES study.

18-02-2022 | Oncology | News | Article

​​​​​​​PROpel: mCRPC patients benefit from add-on olaparib

Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer, show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

18-02-2022 | Oncology | News | Article

Adding niraparib to abiraterone boosts mutated mCRPC outcomes

Men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations could benefit from the addition of niraparib to first-line abiraterone acetate plus prednisone, suggest phase 3 trial data.

18-02-2022 | Oncology | News | Article

Darolutamide add-on prolongs survival in mHSPC

Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, show data from the phase 3 ARASENS trial.

17-02-2022 | Oncology | News | Article

Health-related QoL data support olaparib use in HRR-mutated mCRPC

Olaparib use is associated with reduced pain burden and better preservation of health-related quality of life relative to control treatments in men with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM alterations, research shows.

10-02-2022 | Oncology | News | Article

Niraparib promising in patients with mCRPC and DNA repair gene defects

Niraparib has antitumor activity and manageable toxicity in men with pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, shows a phase 2 trial.

01-02-2022 | Oncology | News | Article

Nonselective beta blockers linked to reduced risk for prostate cancer recurrence

Taking nonselective, but not selective, beta blockers at the time of radical prostatectomy may decrease the risk for prostate cancer recurrence, findings indicate.

28-01-2022 | Oncology | News | Article

Studies confirm add-on ADT benefit in localized prostate cancer, refine optimal duration

A meta-analysis has confirmed the benefit of adding androgen deprivation therapy to radiotherapy for localized prostate cancer, and a cohort study has provided guidance on the optimal duration of the therapy.

11-01-2022 | Oncology | News | Article

Better outcomes with radiotherapy for Black versus White prostate cancer patients

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

05-01-2022 | Oncology | News | Article

HRQoL data reported for ENZAMET trial of enzalutamide in metastatic HSPC

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.